RESUMO
Adenosine has been reported to be transported by equilibrative nucleoside transporter 4 (ENT4), encoded by the SLC29A4 gene, in an acidic pH-dependent manner. This makes hENT4 of interest as a therapeutic target in acidic pathologies where adenosine is protective (e.g. vascular ischaemia). We examined the pH-sensitivity of nucleoside influx and efflux by hENT4 using a recombinant transfection model that lacks the confounding influences of other nucleoside transporters (PK15-NTD). We established that [3H]2-chloroadenosine, which is resistant to metabolism by adenosine deaminase, is a substrate for hENT4. Transport of [3H]2-chloroadenosine at a pH of 6.0 in PK15-NTD cells stably transfected with SLC29A4 was biphasic, with a low capacity (Vmax ~ 30 pmol/mg/min) high-affinity component (Km ~ 50 µM) apparent at low substrate concentrations, which shifted to a high capacity (Vmax ~ 500 pmol/mg/min) low affinity system (Km > 600 µM) displaying positive cooperativity at concentrations above 200 µM. Only the low affinity component was observed at a neutral pH of 7.5 (Km ~ 2 mM). Efflux of [3H]2-chloroadenosine from these cells was also enhanced by more than 4-fold at an acidic pH. Enhanced influx and efflux of nucleosides by hENT4 under acidic conditions supports its potential as a therapeutic target in pathologies such as ischaemia-reperfusion injury.
Assuntos
2-Cloroadenosina/metabolismo , Proteínas de Transporte de Nucleosídeo Equilibrativas/química , Proteínas de Transporte de Nucleosídeo Equilibrativas/metabolismo , Trítio/química , 2-Cloroadenosina/química , Animais , Transporte Biológico , Linhagem Celular , Proteínas de Transporte de Nucleosídeo Equilibrativas/genética , Humanos , Concentração de Íons de Hidrogênio , Cinética , Suínos , TransfecçãoRESUMO
2-Chloro-2'-deoxyadenosine (cladribine, 1) was acylated with valproic acid (2) under various reaction conditions yielding 2-chloro-2'-deoxy-3',5'-O-divalproyladenosine (3) as well as the 3'-O- and 5'-O-monovalproylated derivatives, 2-chloro-2'-deoxy-3'-O-valproyladenosine (4) and 2-chloro-2'-deoxy-5'-O-valproyladenosine (5), as new co-drugs. In addition, 6-azauridine-2',3'-O-(ethyl levulinate) (8) was valproylated at the 5'-OH group (â9). All products were characterized by 1 H- and 13 C-NMR spectroscopy and ESI mass spectrometry. The structure of the by-product 6 (N-cyclohexyl-N-(cyclohexylcarbamoyl)-2-propylpentanamide), formed upon valproylation of cladribine in the presence of N,N-dimethylaminopyridine and dicyclohexylcarbodiimide, was analyzed by X-ray crystallography. Cladribine as well as its valproylated co-drugs were tested upon their cancerostatic/cancerotoxic activity in human astrocytoma/oligodendroglioma GOS-3 cells, in rat malignant neuro ectodermal BT4Ca cells, as well as in phorbol-12-myristate 13-acetate (PMA)-differentiated human THP-1 macrophages. The most important result of these experiments is the finding that only the 3'-O-valproylated derivative 4 exhibits a significant antitumor activity while the 5'-O- as well as the 3',5'-O-divalproylated cladribine derivatives 3 and 5 proved to be inactive.
Assuntos
2-Cloroadenosina/análogos & derivados , Antineoplásicos/farmacologia , Azauridina/farmacologia , Desoxiadenosinas/farmacologia , Ácido Valproico/farmacologia , 2-Cloroadenosina/síntese química , 2-Cloroadenosina/química , 2-Cloroadenosina/farmacologia , Animais , Antineoplásicos/síntese química , Antineoplásicos/química , Azauridina/síntese química , Azauridina/química , Proliferação de Células/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Desoxiadenosinas/síntese química , Desoxiadenosinas/química , Relação Dose-Resposta a Droga , Ensaios de Seleção de Medicamentos Antitumorais , Humanos , Interações Hidrofóbicas e Hidrofílicas , Estrutura Molecular , Ratos , Relação Estrutura-Atividade , Células Tumorais Cultivadas , Ácido Valproico/síntese química , Ácido Valproico/químicaRESUMO
The oncogenic activation of the rearranged during transfection (RET) proto-oncogene has a main role in the pathogenesis of medullary thyroid cancer (MTC). Several lines of evidence suggest that RET function could be influenced by cyclic AMP (cAMP)-dependent protein kinase A (PKA) activity. We evaluated the in vitro anti-tumor activity of 8-chloroadenosine-3',5'-cyclic monophosphate (8-Cl-cAMP) and PKA type I-selective cAMP analogs [equimolar combination of the 8-piperidinoadenosine-3',5'-cyclic monophosphate (8-PIP-cAMP) and 8-hexylaminoadenosine-3',5'-cyclic monophosphate (8-HA-cAMP) in MTC cell lines (TT and MZ-CRC-1)]. 8-Cl-cAMP and the PKA I-selective cAMP analogs showed a potent anti-proliferative effect in both cell lines. In detail, 8-Cl-cAMP blocked significantly the transition of TT cell population from G2/M to G0/G1 phase and from G0/G1 to S phase and of MZ-CRC-1 cells from G0/G1 to S phase. Moreover, 8-Cl-cAMP induced apoptosis in both cell lines, as demonstrated by FACS analysis for annexin V-FITC/propidium iodide, the activation of caspase-3 and PARP cleavage. On the other hand, the only effect induced by PKA I-selective cAMP analogs was a delay in G0/G1-S and S-G2/M progression in TT and MZ-CRC-1 cells, respectively. In conclusion, these data demonstrate that cAMP analogs, particularly 8-Cl-cAMP, significantly suppress in vitro MTC proliferation and provide rationale for a potential clinical use of cAMP analogs in the treatment of advanced MTC.
Assuntos
8-Bromo Monofosfato de Adenosina Cíclica/análogos & derivados , Antineoplásicos/farmacologia , Carcinoma Neuroendócrino/patologia , Proliferação de Células/efeitos dos fármacos , AMP Cíclico/análogos & derivados , Neoplasias da Glândula Tireoide/patologia , 2-Cloroadenosina/análogos & derivados , 2-Cloroadenosina/química , 8-Bromo Monofosfato de Adenosina Cíclica/farmacologia , Aminas/química , Apoptose/efeitos dos fármacos , Ciclo Celular/efeitos dos fármacos , Linhagem Celular Tumoral , AMP Cíclico/farmacologia , Proteínas Quinases Dependentes de AMP Cíclico/metabolismo , Humanos , Sistema de Sinalização das MAP Quinases/efeitos dos fármacos , Piperidinas/farmacologia , Proto-Oncogene MasRESUMO
Ascamycin (ACM) and dealanylascamycin (DACM) are nucleoside antibiotics elaborated by Streptomyces sp. JCM9888. The later shows broad spectrum inhibition activity to various gram-positive and gram-negative bacteria, eukaryotic Trypanosoma and is also toxic to mice, while ascamycin is active against very limited microorganisms, such as Xanthomonas. Both compounds share an unusual 5'-O-sulfonamide moiety which is attached to an adenosine nucleoside. In this paper, we first report on the 30 kb gene cluster (23 genes, acmA to acmW) involved in the biosynthesis of these two antibiotics and a biosynthetic assembly line was proposed. Of them, six genes (AcmABGKIW) are hypothetical genes involved in 5'-O-sulfonamide formation. Two flavin adenine dinucleotide (FAD)-dependent chlorinase genes acmX and acmY were characterized which are significantly remote from acmA-W and postulated to be required for adenine C2-halogenation. Notably gene disruption of acmE resulted in a mutant which could only produce dealanylascamycin but was blocked in its ability to biosynthesize ascamycin, revealing its key role of conversion of dealanylascamycin to ascamycin.
Assuntos
2-Cloroadenosina/análogos & derivados , Adenosina/análogos & derivados , Genes Bacterianos , Streptomyces/genética , Streptomyces/metabolismo , 2-Cloroadenosina/química , 2-Cloroadenosina/metabolismo , Adenosina/química , Adenosina/genética , Adenosina/metabolismo , Dados de Sequência Molecular , Família Multigênica , Sulfonamidas/química , Sulfonamidas/metabolismoRESUMO
8-Chloro-adenosine (8CA) has shown promise in hematologic and solid tumor models and is in a phase I clinical trial. However, 8CA is intensively metabolized shortly after i.v. administration, with a t(1/2ß) of approximately 1h. Many carriers have failed to encapsulate 8CA efficiently. To improve its pharmacokinetic properties, 8-chloro-adenosine-5'-O-stearate (8CAS), a lipophilic octadecanoyl analogue of 8CA, was synthesized and incorporated into pegylated liposomes. The liposomes, comprising egg phosphatidylcholine, cholesterol and poly (ethylene glycol) 2000-distearoyl phosphatidylethanolamine (PEG-DSPE), had mean diameters of approximately 100 nm and an entrapment efficiency of 69-86%. MTT assays showed that the cytotoxicity of 8CAS and its pegylated liposomes (8CAS-PL) were retained, with IC(50) values of 1.0 µM and 1.9 µM at 72 h on MCF-7 cells, respectively, slightly higher than that of 8CA (0.6 µM). Pharmacokinetic studies in rats after i.v. injection showed that both 8CAS and 8 CAS-PL had increased elimination half-lives (t(1/2), 128.4, 249.2 vs. 74.7 min), decreased clearance rates (Cl, 0.0135, 0.00875 vs. 0.2398 L/min/kg) and increased area under the concentration-time curve (AUC(0-∞), 741.4, 1163.6 vs. 42.0 mg min/L) compared to 8CA. No obvious hematological toxicity was seen for Kunming mice receiving i.v. 8CA or 8CAS-PL at a dosage of 10mg/kg daily. These results indicate that the lipophilic derivation of 8CA and the incorporation of 8CAS is an effective strategy to improve the bioavailability of 8CA.
Assuntos
2-Cloroadenosina/análogos & derivados , Antineoplásicos/farmacocinética , 2-Cloroadenosina/sangue , 2-Cloroadenosina/química , 2-Cloroadenosina/farmacocinética , Animais , Antineoplásicos/sangue , Antineoplásicos/química , Linhagem Celular Tumoral , Sobrevivência Celular/efeitos dos fármacos , Ácidos Graxos/química , Humanos , Lipossomos , Masculino , Polietilenoglicóis/química , Ratos , Ratos Sprague-DawleyRESUMO
8-Chloroadenosine (8-Cl-Ado) is a ribosyl nucleoside analog currently in phase I testing for the treatment of chronic lymphocytic leukemia (CLL). 8-Cl-Ado activity is dependent on adenosine kinase and requires intracellular accumulation of 8-Cl-Ado as mono-, di-, and tri-phosphates. In the current study with four mantle cell lymphoma cell lines, we report a new major metabolic pathway for 8-Cl-Ado intracellular metabolism, the formation of succinyl-8-chloro-adenosine (S-8-Cl-Ado) and its monophosphate (S-8-Cl-AMP). 8-Cl-AMP levels were highly associated with S-8-Cl-AMP levels and reached a steady-state prior to the secondary metabolites, 8-Cl-ATP and S-8-Cl-Ado. Consistent with fumarate as a required substrate for formation of succinyl-8-Cl-adenylate metabolites, the S-8-Cl-adenylate concentrations in multiple cell lines were associated with fumarate loss. The distribution of metabolites was also altered using the energy metabolism modifiers, metformin and oligomycin. The rates of succinyl-8-Cl-adenylate metabolism were enhanced by increasing the intracellular fumarate concentrations after metformin co-treatment. In addition, the S-8-Cl-AMP concentrations were increased after acute inhibition of ATP synthase by oligomycin. We conclude that 8-Cl-Ado metabolism not only affects intracellular purine metabolism; 8-Cl-Ado conversion to succinyl analogs ties its metabolism to the citric acid cycle by reduction of the fumarate pool.
Assuntos
2-Cloroadenosina/análogos & derivados , Antineoplásicos/farmacocinética , Metabolismo Energético/efeitos dos fármacos , Fumaratos/metabolismo , Linfoma de Célula do Manto/tratamento farmacológico , Ácido Succínico/metabolismo , 2-Cloroadenosina/química , 2-Cloroadenosina/farmacocinética , 8-Bromo Monofosfato de Adenosina Cíclica/análogos & derivados , 8-Bromo Monofosfato de Adenosina Cíclica/metabolismo , Antineoplásicos/química , Linhagem Celular Tumoral , Ciclo do Ácido Cítrico/efeitos dos fármacos , Relação Dose-Resposta a Droga , Humanos , Hipoglicemiantes/farmacologia , Linfoma de Célula do Manto/metabolismo , Linfoma de Célula do Manto/patologia , Metformina/farmacologia , Oligomicinas/farmacologia , Purinas/metabolismo , Ácido Succínico/química , Desacopladores/farmacologiaRESUMO
8-Chloroadenosine (8-Cl-Ado) is a ribonucleoside analogue that is currently in clinical trial for chronic lymphocytic leukemia. Based on the decline in cellular ATP pool following 8-Cl-Ado treatment, we hypothesized that 8-Cl-ADP and 8-Cl-ATP may interfere with ATP synthase, a key enzyme in ATP production. Mitochondrial ATP synthase is composed of two major parts; F(O) intermembrane base and F1 domain, containing alpha and beta subunits. Crystal structures of both alpha and beta subunits that bind to the substrate, ADP, are known in tight binding (alpha(dp)beta(dp)) and loose binding (alpha(tp)beta(tp)) states. Molecular docking demonstrated that 8-Cl-ADP/8-Cl-ATP occupied similar binding modes as ADP/ATP in the tight and loose binding sites of ATP synthase, respectively, suggesting that the chlorinated nucleotide metabolites may be functional substrates and inhibitors of the enzyme. The computational predictions were consistent with our whole cell biochemical results. Oligomycin, an established pharmacological inhibitor of ATP synthase, decreased both ATP and 8-Cl-ATP formation from exogenous substrates, however, did not affect pyrimidine nucleoside analogue triphosphate accumulation. Synthesis of ATP from ADP was inhibited in cells loaded with 8-Cl-ATP. These biochemical studies are in consent with the computational modeling; in the alpha(tp)beta(tp) state 8-Cl-ATP occupies similar binding as ANP, a non-hydrolyzable ATP mimic that is a known inhibitor. Similarly, in the substrate binding site (alpha(dp)beta(dp)) 8-Cl-ATP occupies a similar position as ATP mimic ADP-BeF(3)(-). Collectively, our current work suggests that 8-Cl-ADP may serve as a substrate and the 8-Cl-ATP may be an inhibitor of ATP synthase.
Assuntos
2-Cloroadenosina/análogos & derivados , Complexos de ATP Sintetase/efeitos dos fármacos , Adenosina/farmacologia , 2-Cloroadenosina/química , 2-Cloroadenosina/farmacologia , Complexos de ATP Sintetase/química , Adenosina/química , Antineoplásicos/química , Antineoplásicos/farmacologia , Glicólise/efeitos dos fármacos , Glicólise/fisiologia , Halogenação , Hidrólise , Modelos Moleculares , Consumo de Oxigênio/efeitos dos fármacos , Ligação Proteica , Conformação Proteica/efeitos dos fármacosRESUMO
Cladribine, i.e.2-deoxy-Chloroadenosine is currently in use as chemotherapeutic agent in chronic lymphoid malignancies and pediatric acute myelogenous leukemia whereas the structurally related counterpart, 2-Chloroadenosine, has been less studied. Nevertheless, 2-Chloroadenosine has been shown to be capable of inducing apoptosis in several cell lines by acting either via adenosine receptors or via uptake that is followed by metabolic transformations leading to nucleotide analogues, i.e. antimetabolites effective in the treatment of a variety of malignancies. Triphosphate nucleoside analogues show specificity for cell in S-phase, inhibit DNA synthesis and kill the cells by mechanisms still largely unknown. 2-Chloroadenosine, at low micromolar concentration, acts as a metabolic precursor of an S-phase specific nucleoside analogue in human prostate cancer PC3 cells and inhibits DNA synthesis thereby leading to accumulation of cells in the S-phase. However, although responsible for the acquisition of resistance, the adenosine derivative is capable of sensitising the cells to the action of other antineoplastic agents and the ability of nucleoside analogues to trigger cell cycle arrest can be exploited to maximize cytotoxicity in combination with cell cycle checkpoint disregulators. 2-Chloroadenosine, in combination with Docetaxel, known to improve the survival of hormone-refractory prostate cancer patients, further decreases in vitro PC3 cell proliferation and invasiveness. Moreover, 2-Chloroadenosine is capable of modulating PAR-1 and IL-23 gene expression suggesting a modulation of cancer metastasis and immune system activity. The present review summarizes research performed in our laboratory to propose a novel role for 2-Chloroadenosine as an anticancer agent.
Assuntos
2-Cloroadenosina , Antineoplásicos , Neoplasias da Próstata/tratamento farmacológico , 2-Cloroadenosina/química , 2-Cloroadenosina/farmacologia , 2-Cloroadenosina/uso terapêutico , Antineoplásicos/química , Antineoplásicos/farmacologia , Antineoplásicos/uso terapêutico , Apoptose/efeitos dos fármacos , Linhagem Celular Tumoral , Sobrevivência Celular/efeitos dos fármacos , Expressão Gênica/efeitos dos fármacos , Humanos , Interleucina-23/genética , Masculino , Estrutura Molecular , Neoplasias da Próstata/genética , Neoplasias da Próstata/patologia , Receptor PAR-1/genéticaRESUMO
8-Chloroadenosine (8-Cl-Ado) has shown potential as a chemotherapeutic agent for the treatment of multiple myeloma and certain leukemias. 8-Cl-Ado treatment leads to a decrease in global RNA levels and incorporation of the analog into cellular RNA in malignant cells. To investigate the effects of 8-Cl-Ado modifications on RNA structure and function, an 8-Cl-Ado phosphoramidite and controlled-pore glass support were synthesized and used to introduce 8-Cl-Ado at internal and 3'- terminal positions, respectively. RNA oligonucleotides containing 8-chloroadenine (8-Cl-A) residues were synthesized and hybridized with complementary RNA strands. Circular dichroism spectroscopy of the resulting RNA duplexes revealed that the modified nucleobase does not perturb the overall A-form helix geometry. The thermal stabilities of 8-Cl-Ado modified duplexes were determined by UV thermal denaturation analysis and were compared with analogous natural duplexes containing standard and mismatched base pairs. The 8-Cl-Ado modification destabilizes RNA duplexes by approximately 5 kcal/mole, approximately as much as a U:U mismatched base pair. The duplex destabilization of 8-Cl-A may result from perturbation of Watson-Crick base pairing induced by conformational preferences of 8-halogenated nucleosides.
Assuntos
2-Cloroadenosina/análogos & derivados , 2-Cloroadenosina/química , 2-Cloroadenosina/síntese química , RNA/química , RNA/síntese química , 2-Cloroadenosina/efeitos da radiação , Dicroísmo Circular , Temperatura Alta , Estrutura Molecular , Desnaturação de Ácido Nucleico/efeitos da radiação , Hibridização de Ácido Nucleico , RNA/efeitos da radiação , Estabilidade de RNA/efeitos da radiação , RNA Complementar/química , Raios UltravioletaRESUMO
Previous reports raised question as to whether 8-chloro-cyclic adenosine 3,5-monophosphate (8-Cl-cAMP) is a prodrug for its metabolite, 8-Cl-adenosine which exerts growth inhibition in a broad spectrum of cancer cells. The present study was carried out to clarify overall cellular affects of 8-Cl-cAMP and 8-Cl-adenosine on SK-N-DZ human neuroblastoma cells by systematically characterizing gene expression using radioactive human cDNA microarray. Microarray was prepared with PCR-amplified cDNA of 2,304 known genes spotted on nylon membranes, employing (33)P-labeled cDNAs of SK-N-DZ cells as a probe. The expression levels of approximately 100 cDNAs, representing about 8% of the total DNA elements on the array, were altered in 8-Cl-adenosine- or 8-Cl-cAMP-treated cells, respectively. The genome-wide expression of the two samples exhibited partial overlaps; different sets of up-regulated genes but the same set of down-regulated genes. 8-Cl-adenosine treatment up-regulated genes involved in differentiation and development (LIM protein, connexin 26, neogenin, neurofilament triplet L protein and p21(WAF1/CIP1)) and immune response such as natural killer cells protein 4, and down-regulated ones involved in proliferation and transformation (transforming growth factor-beta, DYRK2, urokinase-type plasminogen activator and proteins involved in transcription and translation) which were in close parallel with those by 8-Cl-cAMP. Our results indicated that the two drugs shared common genomic pathways for the down-regulation of certain genes, but used distinct pathways for the up-regulation of different gene clusters. Based on the findings, we suggest that the anti-cancer activity of 8-Cl-cAMP results at least in part through 8-Cl-adenosine. Thus, the systematic use of DNA arrays can provide insight into the dynamic cellular pathways involved in anticancer activities of chemotherapeutics.
Assuntos
2-Cloroadenosina/análogos & derivados , 2-Cloroadenosina/farmacologia , 8-Bromo Monofosfato de Adenosina Cíclica/análogos & derivados , 8-Bromo Monofosfato de Adenosina Cíclica/farmacologia , Antineoplásicos/farmacologia , Perfilação da Expressão Gênica , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Neuroblastoma/genética , 2-Cloroadenosina/química , 8-Bromo Monofosfato de Adenosina Cíclica/química , Antineoplásicos/química , Western Blotting , Genoma Humano , Humanos , Análise de Sequência com Séries de Oligonucleotídeos , Reprodutibilidade dos Testes , Células Tumorais Cultivadas , Regulação para Cima/efeitos dos fármacosRESUMO
Nucleoside analogues (NA) are essential components of AML induction therapy (cytosine arabinoside), effective treatments of lymphoproliferative disorders (fludarabine, cladribine) and are also used in the treatment of some solid tumors (gemcitabine). These important compounds share some general common characteristics, namely in terms of requiring transport by specific membrane transporters, metabolism and interaction with intracellular targets. However, these compounds differ in regard to the types of transporters that most efficiently transport a given compound, and their preferential interaction with certain targets which may explain why some compounds are more effective against rapidly proliferating tumors and others on neoplasia with a more protracted evolution. In this review, we analyze the available data concerning mechanisms of action of and resistance to NA, with particular emphasis on recent advances in the characterization of nucleoside transporters and on the potential role of activating or inactivating enzymes in the induction of clinical resistance to these compounds. We performed an extensive search of published in vitro and clinical data in which the levels of expression of nucleoside-activating or inactivating enzymes have been correlated with tumor response or patient outcome. Strategies aiming to increase the intracellular concentrations of active compounds are presented.
Assuntos
2-Cloroadenosina/análogos & derivados , Antimetabólitos Antineoplásicos/farmacologia , Citosina/análogos & derivados , Resistencia a Medicamentos Antineoplásicos/fisiologia , Nucleosídeos/farmacologia , Vidarabina/análogos & derivados , 2-Cloroadenosina/química , 2-Cloroadenosina/farmacologia , 5'-Nucleotidase/metabolismo , Doença Aguda , Animais , Antimetabólitos Antineoplásicos/química , Antimetabólitos Antineoplásicos/farmacocinética , Antimetabólitos Antineoplásicos/uso terapêutico , Arabinonucleosídeos/química , Arabinonucleosídeos/farmacologia , Transporte Biológico , Proteínas de Transporte/metabolismo , Citarabina/química , Citarabina/farmacologia , Citidina Desaminase/metabolismo , Citosina/química , Citosina/farmacologia , Reparo do DNA/efeitos dos fármacos , Replicação do DNA/efeitos dos fármacos , DNA Polimerase Dirigida por DNA/metabolismo , Desoxiadenosinas/química , Desoxiadenosinas/farmacologia , Desoxicitidina/análogos & derivados , Desoxicitidina/química , Desoxicitidina/farmacologia , Desoxicitidina Quinase/metabolismo , Dioxolanos/química , Dioxolanos/farmacologia , Fatores de Crescimento de Células Hematopoéticas/farmacologia , Humanos , Leucemia Mieloide/tratamento farmacológico , Transtornos Linfoproliferativos/tratamento farmacológico , Células-Tronco Neoplásicas/efeitos dos fármacos , Nucleosídeos/química , Nucleosídeos/farmacocinética , Nucleosídeos/uso terapêutico , Fosforilação , Fosfotransferases (Aceptor do Grupo Álcool)/metabolismo , Indução de Remissão , Ribonucleotídeo Redutases/antagonistas & inibidores , Ribonucleotídeo Redutases/metabolismo , Vidarabina/química , Vidarabina/farmacologia , GencitabinaRESUMO
Unsaturated free fatty acids and adenosine operate two neuromodulatory systems with opposite effects on neuronal function. Here, we tested if fatty acids controlled inhibitory adenosine A1 receptors. Arachidonate (AA, 10 microM) decreased the Bmax of an A1 receptor agonist, (R)-[3H]phenylisopropyladenosine (PIA; from 812 to 267 fmol x mg(-1) protein), and antagonist, [3H]1,3-dipropyl-8-cyclopentylxanthine (DPCPX; from 994 to 311 fmol x mg(-1) protein) and decreased the Kd of [3H]PIA (from 1.20 to 0.57 nM) binding to brain membranes of young adult rats (2 months old), these effects being mimicked by other cis but not trans unsaturated or saturated fatty acids. AA (10 microM) increased the potency of the A1 receptor agonist, 2-chloroadenosine to inhibit hippocampal synaptic transmission in young adult rats (EC50 decreased from 337 to 237 nM), which may constitute a safety feedback mechanism to control AA-induced neurotoxicity. Upon aging, there were increased free fatty acid levels and a concomitant decreased density of A1 receptors. This was more marked in hippocampal nerve terminals of aged rats (24 months old) and may be the determinant factor contributing to the lower potency of 2-choloroadenosine in aged rats (EC50 = 955 nM), in spite of the decreased Kd of PIA binding upon aging. The effects of AA on A1 receptor binding were attenuated upon aging, AA being devoid of effects in aged rats. Accordingly, AA (10 microM) failed to modify the potency of 2-choloroadenosine in aged rats (EC50 = 997 nM). However, albumin, which quenches free fatty acids, increased A1 receptor density by 65% and 2-chloroadenosine potency (EC50 = 703 nM) in aged rats, suggesting that the increased fatty acids levels in aged rats may contribute to the decreased potency of A1 receptor agonists in aged rats. Also, the observed saturation of the control by AA of A1 receptors may contribute to the decreased adaptability of neuromodulation to different firing conditions in aged rats.
Assuntos
Envelhecimento , Encéfalo/metabolismo , Receptores Purinérgicos P1/química , 2-Cloroadenosina/química , Fatores Etários , Animais , Ácido Araquidônico/farmacologia , Sítios de Ligação , Relação Dose-Resposta a Droga , Eletrofisiologia , Hipocampo/metabolismo , Cinética , Masculino , Fenilisopropiladenosina/química , Ligação Proteica , Ratos , Ratos Wistar , Fatores de Tempo , Xantinas/farmacologiaRESUMO
The stability of the naturally occurring nucleoside, adenosine, and two synthetic chlorine-containing analogues, 2-chloroadenosine and 5'-chloro-5'-deoxyadenosine was studied using high performance liquid chromatography (LC) and liquid chromatography in combination with mass spectrometry (LC/MS). The stability of the examined nucleosides over pH range of 2-10 and at temperatures 40, 60 and 80 degrees C was measured using an LC method, whereas the products of hydrolysis were identified using LC/MS. The LC data indicated that the hydrolysis of the nucleosides followed pseudo-first order kinetics. The MS data proved that the fragment ions at m/z 136.3 and 170.3 referred to the hydrolytic products, adenine and 2-chloroadenine, respectively. The calculated values of the hydrolysis rate constant and half-life indicated that the presence of chlorine atom in the nucleoside base moiety increases apparently the stability of 2-chloroadenosine against acid hydrolysis compared to 5'-chloro-5'-deoxyadenosine and adenosine.
Assuntos
2-Cloroadenosina/química , Cromatografia Líquida/métodos , Cladribina/química , Espectrometria de Massas/métodos , Estabilidade de Medicamentos , Hidrólise , CinéticaRESUMO
We previously described that 2-chloroadenosine (2CA) and 2-chloro-2'-deoxyadenosine (2CdA) induced apoptosis in human peripheral blood mononuclear cells (PBMC). In this study we tested different adenosine analogues on PBMC and we found that the modifications introduced in the 2CA structure prevented the molecule from exerting its apoptotic effect. On the other hand, substitutions on 2CdA are tolerated, although with a significant decrease in activity.
Assuntos
Apoptose/efeitos dos fármacos , Linfócitos/efeitos dos fármacos , 2-Cloroadenosina/análogos & derivados , 2-Cloroadenosina/química , 2-Cloroadenosina/farmacologia , Células Cultivadas , Desoxiadenosinas/química , Desoxiadenosinas/farmacologia , Citometria de Fluxo , Humanos , Linfócitos/fisiologia , Modelos Químicos , Propídio/farmacologia , Relação Estrutura-AtividadeRESUMO
Not all patients with B-cell chronic lymphocytic leukemia require therapy. Patients with stable early stage disease do not need treatment, whereas those with progressive early stage disease or advanced stage disease do. The standard initial therapeutic regimen is orally administered chlorambucil and prednisone. The overall response rate to initial chemotherapy is approximately 80%; the median duration of response is 2 years. Conventional chemotherapy, however, does not provide long-term remission for patients in whom the disease becomes refractory to chlorambucil. For such patients, alternative treatment approaches including the use of purine nucleoside analogues or bone marrow transplantation may be considered. Fludarabine, 2-chlorodeoxyadenosine, and pentostatin are three analogues of the naturally occurring deoxypurine nucleoside, deoxyadenosine, and all have shown activity in chronic lymphocytic leukemia. Overall response rates of 57 to 79% have been reported with use of fludarabine. A dose-related toxic effect is myelosuppression. Experience with bone marrow transplantation is limited. The number of eligible patients with histocompatible sibling donors is low. The future role of allogeneic bone marrow transplantation in patients with B-cell chronic lymphocytic leukemia will depend on the ability to identify poor-risk groups and the long-term therapeutic efficacy of the purine nucleoside analogues or other new agents.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Leucemia Linfocítica Crônica de Células B/terapia , 2-Cloroadenosina/administração & dosagem , 2-Cloroadenosina/análogos & derivados , 2-Cloroadenosina/química , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/farmacologia , Medula Óssea/efeitos dos fármacos , Transplante de Medula Óssea/normas , Clorambucila/administração & dosagem , Desoxiadenosinas/administração & dosagem , Desoxiadenosinas/química , Relação Dose-Resposta a Droga , Teste de Histocompatibilidade , Humanos , Leucemia Linfocítica Crônica de Células B/mortalidade , Pentostatina/administração & dosagem , Pentostatina/química , Prednisona/administração & dosagem , Prognóstico , Taxa de Sobrevida , Vidarabina/administração & dosagem , Vidarabina/análogos & derivados , Vidarabina/químicaRESUMO
2-Chlorodeoxyadenosine (CdA) is active in chronic lymphocytic leukemia, hairy-cell leukemia, and low-grade lymphomas. In part, this spectrum of activity may be attributable to the selective toxicity of CdA to nondividing lymphocytes and monocytes. However, CdA is unstable at acidic pH and is degraded by bacterial nucleoside phosphorylases. The present experiments demonstrate that the 2'-arabino-fluoro derivative of CdA, designated CAFdA, is also directly toxic to quiescent lymphocytes and macrophages. Unlike CdA, CAFdA was stable at pH 2 and resisted degradation by Escherichia coli nucleoside phosphorylase. Cell killing was preceded by the formation of DNA strand breaks and could be prevented by supplementation of the medium with deoxycytidine. The initial DNA damage initiated the pattern of oligonucleosomal DNA fragmentation characteristic of apoptosis. Mutant lymphoblasts, deficient in deoxycytidine kinase, with elevated cytoplasmic 5'-nucleotidase, or with expanded deoxynucleotide pools secondary to increased ribonucleotide reductase activity, were cross-resistant to both CAFdA and CdA toxicity. One-week oral treatment with CAFdA (1 mg/ml in drinking water) achieved an average plasma concentration of 0.56 microM and eliminated 90% of chronic lymphocytic leukemia cells transplanted into severe combined immunodeficiency (scid) mice. Under the same conditions, CdA was much less active. Collectively, these results suggest that CAFdA could be effective as an oral agent in indolent lymphoproliferative diseases and in autoimmune diseases where lymphocyte and monocyte depletion is desirable.
Assuntos
2-Cloroadenosina/análogos & derivados , Antimetabólitos Antineoplásicos/toxicidade , Arabinonucleosídeos/toxicidade , Morte Celular/efeitos dos fármacos , Dano ao DNA , Desoxiadenosinas/toxicidade , Linfócitos/efeitos dos fármacos , Monócitos/efeitos dos fármacos , 2-Cloroadenosina/química , 2-Cloroadenosina/farmacocinética , 2-Cloroadenosina/toxicidade , Nucleotídeos de Adenina , Animais , Antimetabólitos Antineoplásicos/química , Antimetabólitos Antineoplásicos/farmacocinética , Arabinonucleosídeos/química , Arabinonucleosídeos/farmacocinética , Cladribina , Clofarabina , DNA/efeitos dos fármacos , Desoxiadenosinas/química , Desoxiadenosinas/farmacocinética , Leucemia de Células Pilosas/tratamento farmacológico , Leucemia Linfocítica Crônica de Células B/tratamento farmacológico , Camundongos , Camundongos SCIDAssuntos
2-Cloroadenosina/análogos & derivados , Desoxiadenosinas/uso terapêutico , Leucemia de Células Pilosas/tratamento farmacológico , Transtornos Linfoproliferativos/tratamento farmacológico , 2-Cloroadenosina/química , 2-Cloroadenosina/uso terapêutico , Cladribina , Desoxiadenosinas/química , HumanosRESUMO
Adenosine deaminase (ADA), a purine salvage pathway enzyme, appears to play a key role in normal lymphocyte growth, development, and differentiation. Three new purine nucleoside analogues, deoxycoformycin, fludarabine, and 2-chlorodeoxyadenosine, affect the normal function of the purine salvage pathway by inhibiting ADA or by acting as analogs of the ADA substrates. These agents show significant activity in the treatment of chronic B-cell leukemias and low-grade lymphomas. The pharmacology, mechanism of action, and clinical usefulness of these agents are discussed.